A single institution retrospective study of sargramostim (glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) in patients with pediatric malignancies and invasive fungal diseases that were refractory to antifungal therapy and treated adjunctively
Latest Information Update: 22 Dec 2022
At a glance
- Drugs Sargramostim (Primary)
- Indications Mycoses
- Focus Therapeutic Use
Most Recent Events
- 22 Dec 2022 New trial record
- 15 Dec 2022 According to a Partner Therapeutics media release, this research was led by Thomas J. Walsh, MD, PhD (Hon), FIDSA, FAAM, FECMM, of the Transplantation-Oncology Infectious Disease Program at Weill Cornell Medicine and Center for Innovative Therapeutics and Diagnostics, and Tempe K. Chen, MD, of MemorialCare Miller Children's & Women's Hospital Long Beach and Division of Infectious Diseases at University of California Irvine School of Medicine.
- 15 Dec 2022 Results (N=15) published in a Partner Therapeutics media release.